StockNews.AI
AKBA
StockNews.AI
166 days

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

1. Akebia plans Q4 and full-year financial results release on March 13, 2025. 2. A conference call will discuss financial results at 8:00 a.m. ET on March 13. 3. Live webcast of the call to be available via Akebia's investor website. 4. Akebia is focused on improving the lives of those with kidney disease. 5. Company aims to provide updates on business highlights along with results.

3m saved
Insight
Article

FAQ

Why Neutral?

Regular earnings report announcement, historically neutral impact on stock prices.

How important is it?

Earnings reports often affect short-term stock prices due to investor sentiment but may not indicate long-term trends.

Why Short Term?

Immediate investor interest may shift based on reported figures, but longer term depends on performance.

Related Companies

AMGNREGNVRTX
Akebia to Host Conference Call on March 13, 2025, at 8:00 a.m. ET March 06, 2025 08:00 ET  | Source: Akebia Therapeutics, Inc. CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com. About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com

Related News